RWJ 38293

Drug Profile

RWJ 38293

Latest Information Update: 08 Mar 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Neuroprotectants; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders

Most Recent Events

  • 08 Mar 2000 No-Development-Reported for Anxiety disorders in USA (Unknown route)
  • 20 Feb 1997 New profile
  • 20 Feb 1997 Preclinical development for Anxiety disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top